Cycle patents expiration
1. Nityr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10328029 | CYCLE | Pharmaceutical composition |
Jan, 2035
(10 years from now) | |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 26 July, 2017
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: TABLET;ORAL
More Information on Dosage
NITYR family patents
2. Tascenso Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10555902 | CYCLE | Stable fingolimod dosage forms |
Jan, 2036
(11 years from now) | |
| US9925138 | CYCLE | Stable solid fingolimod dosage forms |
Jan, 2036
(11 years from now) | |
| US10925829 | CYCLE | Stable solid fingolimod dosage forms |
Jan, 2036
(11 years from now) | |
Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient
Market Authorisation Date: 23 December, 2021
Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
TASCENSO ODT family patents